Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction

被引:51
作者
Bolshan, Yuri [1 ]
Getlik, Matthaeus [2 ]
Kuznetsova, Ekaterina [1 ]
Wasney, Gregory A. [1 ]
Hajian, Taraneh [1 ]
Poda, Gennadiy [2 ]
Nguyen, Kong T. [1 ]
Wu, Hong [1 ]
Dombrovski, Ludmila [1 ]
Dong, Aiping [1 ]
Senisterra, Guillermo [1 ]
Schapira, Matthieu [1 ]
Arrowsmith, Cheryl H. [1 ]
Brown, Peter J. [1 ]
Al-awar, Rima [2 ]
Vedadi, Masoud [1 ]
Smil, David [1 ]
机构
[1] Univ Toronto, Struct Genom Consortium, MaRS Ctr, Toronto, ON M5G 1L7, Canada
[2] Ontario Inst Canc Res, MaRS Ctr, Toronto, ON M5G 0A3, Canada
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 03期
基金
英国惠康基金;
关键词
WDR5; MLL; SET1 methyltransferase complex; peptide binding site; small molecule antagonists; HISTONE H3; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; CORE COMPLEX; HOX GENES; MLL; METHYLATION; RECOGNITION; METHYLTRANSFERASES; TRANSLOCATIONS;
D O I
10.1021/ml300467n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The WD40-repeat protein WDRS plays a critical role in maintaining the integrity of MLL complexes and fully activating their methyltransferase function. MLL complexes, the trithorax-like family of SET1 methyltransferases, catalyze trimethylation of lysine 4 on histone 3, and they have been widely implicated in various cancers. Antagonism of WDR5 and MLL subunit interaction by small molecules has recently been presented as a practical way to inhibit activity of the MLL1 complex, and N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides were reported as potent and selective antagonists of such an interaction. Here, we describe the protein crystal structure guided optimization of prototypic compound 2 (K-dis = 7 mu M), leading to identification of more potent antagonist 47 (K-dis = 0.3 mu M).
引用
收藏
页码:353 / 357
页数:5
相关论文
共 26 条
  • [1] Hox genes in hematopoiesis and leukemogenesis
    Argiropoulos, B.
    Humphries, R. K.
    [J]. ONCOGENE, 2007, 26 (47) : 6766 - 6776
  • [2] Structural and Biochemical Insights into MLL1 Core Complex Assembly
    Avdic, Vanja
    Zhang, Pamela
    Lanouette, Sylvain
    Groulx, Adam
    Tremblay, Veronique
    Brunzelle, Joseph
    Couture, Jean-Francois
    [J]. STRUCTURE, 2011, 19 (01) : 101 - 108
  • [3] Regulation of MLL1 H3K4 methyltransferase activity by its core components
    Dou, Yali
    Milne, Thomas A.
    Ruthenburg, Alexander J.
    Lee, Seunghee
    Lee, Jae Woon
    Verdine, Gregory L.
    Allis, C. David
    Roeder, Robert G.
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2006, 13 (08) : 713 - 719
  • [4] Open access chemical and clinical probes to support drug discovery
    Edwards, Aled M.
    Bountra, Chas
    Kerr, David J.
    Willson, Timothy M.
    [J]. NATURE CHEMICAL BIOLOGY, 2009, 5 (07) : 436 - 440
  • [5] WRAD: enabler of the SET1-family of H3K4 methyltransferases
    Ernst, Patricia
    Vakoc, Christopher R.
    [J]. BRIEFINGS IN FUNCTIONAL GENOMICS, 2012, 11 (03) : 217 - 226
  • [6] THE T(4-11) CHROMOSOME-TRANSLOCATION OF HUMAN ACUTE LEUKEMIAS FUSES THE ALL-1 GENE, RELATED TO DROSOPHILA-TRITHORAX, TO THE AF-4 GENE
    GU, Y
    NAKAMURA, T
    ALDER, H
    PRASAD, R
    CANAANI, O
    CIMINO, G
    CROCE, CM
    CANAANI, E
    [J]. CELL, 1992, 71 (04) : 701 - 708
  • [7] High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein-Protein Interaction
    Karatas, Hacer
    Townsend, Elizabeth C.
    Cao, Fang
    Chen, Yong
    Bernard, Denzil
    Liu, Liu
    Lei, Ming
    Dou, Yali
    Wang, Shaomeng
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2013, 135 (02) : 669 - 682
  • [8] Chromatin modifications and their function
    Kouzarides, Tony
    [J]. CELL, 2007, 128 (04) : 693 - 705
  • [9] MLL translocations, histone modifications and leukaemia stem-cell development
    Krivtsov, Andrei V.
    Armstrong, Scott A.
    [J]. NATURE REVIEWS CANCER, 2007, 7 (11) : 823 - 833
  • [10] Therapeutic targeting of MLL
    Liedtke, Michaela
    Cleary, Michael L.
    [J]. BLOOD, 2009, 113 (24) : 6061 - 6068